ABL Bio "ROR1 Antibody Patents Registered in Korea and Japan... Targeting Various Cancer Types"

ABL Bio announced on the 3rd that it has completed patent registration in South Korea and Japan for anti-ROR1 antibodies that inhibit ROR1, which is overexpressed in various cancer types including solid tumors and hematologic malignancies, as well as their uses.

ABL Bio CI. [Image provided by ABL Bio]

The company added that the patent rights are guaranteed until 2039, and examinations for patent registration are underway in multiple countries including the United States, China, and Europe.

ROR1 is known to be overexpressed in a variety of cancer types ranging from solid tumors to hematologic malignancies, making it a target for diverse cancers. Accordingly, ABL Bio explained that research and development on ROR1 antibodies are actively progressing among global companies.

Recently, as the value of antibody-drug conjugate (ADC) pipelines targeting ROR1 has been highlighted, the company emphasized that the ROR1 ADC pipeline 'ABL202,' jointly developed by ABL Bio and LegoChem Biosciences and licensed to Seestone Pharmaceuticals, will also attract attention. ABL202 differentiates itself in efficacy and safety by conjugating ABL Bio’s ROR1 antibody with LegoChem Biosciences’ next-generation ADC proprietary technology, which includes a blood-stable linker and a cytotoxic anticancer drug called Pro PBD. The ADC pipeline ABL202, applying ABL Bio’s ROR1 antibody, is currently undergoing clinical trials in the United States, China, and Australia.

Lee Sang-hoon, CEO of ABL Bio, stated, “There is high interest from global pharmaceutical companies in ROR1 targets expressed in both solid tumors and hematologic malignancies, and among them, ABL Bio’s ROR1 has demonstrated excellent antibody efficacy in non-clinical data. We are actively pursuing patent registrations for ROR1 targets in various countries beyond South Korea and Japan, and we will also focus on securing intellectual property rights for new pipelines such as ADCs in the future.”

Meanwhile, ABL Bio announced that it is concretizing its next-generation ADC development strategy, including bispecific antibody ADCs, based on its antibody technology.

This content was produced with the assistance of AI translation services.